Arcturus

Meet the maker of the powdered vaccine that hopes to immunize 4m. Israelis

Israel signed with Arcturus back in July, soon after it struck a deal with Moderna.

|ByMAAYAN JAFFE-HOFFMAN
Arcturus CEO Joseph Payne
A volunteer receives an injection in a human clinical trial for a potential vaccine against the novel coronavirus, at the Baragwanath hospital in Soweto, South Africa, June 24, 2020

Arcturus expects to distribute coronavirus vaccine in early 2021

The California-based company's announcement came as Pfizer said its COVID-19 vaccine is more than 90% effective based on initial trial results.

|ByREUTERS
Bottles labeled "Vaccine" stand near medical syringe in front of "Coronavirus COVID-19" display (illustrative)

Bennett, IIBR slam Health Ministry over coronavirus vaccine trials delay

Were the Health Ministry to give approval for this stage, the IIBR states it would be possible to develop a vaccine as early as 2021.

|ByCELIA JEAN
Bottles labeled "Vaccine" stand near medical syringe in front of "Coronavirus COVID-19" display (illustrative)

Israel signs for 4 million doses of new coronavirus vaccine candidate

Arcturus' vaccine would potentially require only one dose because of its replicating effect. All others in development currently require at least two doses.

|ByMAAYAN JAFFE-HOFFMAN